{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:20:32Z","timestamp":1788009632056,"version":"build-2784847793"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302970"],"award-info":[{"award-number":["82302970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573563"],"award-info":[{"award-number":["81573563"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202408510183"],"award-info":[{"award-number":["202408510183"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018927","name":"Southwest Minzu University","doi-asserted-by":"publisher","award":["2024CXTD16"],"award-info":[{"award-number":["2024CXTD16"]}],"id":[{"id":"10.13039\/501100018927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["ZYN2024205"],"award-info":[{"award-number":["ZYN2024205"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118590","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:28:15Z","timestamp":1768955295000},"page":"118590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Epigenetic enzyme inhibitors targeting DNA, histone, and RNA methylation: Mechanisms and therapeutic applications in cancer"],"prefix":"10.1016","volume":"306","author":[{"given":"Yiman","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1389-0546","authenticated-orcid":false,"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118590_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0022-2836(02)00386-8","article-title":"Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 \u00c5 resolution","volume":"319","author":"Davey","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 Angstrom resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1146\/annurev.bi.49.070180.005343","article-title":"Nucleosome structure","volume":"49","author":"McGhee","year":"1980","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.118590_bib4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1146\/annurev.bi.46.070177.004435","article-title":"Structure of chromatin","volume":"46","author":"Kornberg","year":"1977","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.118590_bib5","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1021\/ja910264z","article-title":"DNA methylation increases nucleosome compaction and rigidity","volume":"132","author":"Choy","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118590_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ije\/dyr184","article-title":"The epigenotype. 1942","volume":"41","author":"Waddington","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.ejmech.2026.118590_bib7","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s12325-020-01379-x","article-title":"The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review","volume":"37","author":"Rugo","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2026.118590_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1101\/sqb.2010.75.007","article-title":"Cancer epigenetics: from disruption of differentiation programs to the emergence of cancer stem cells","volume":"75","author":"Scaffidi","year":"2010","journal-title":"Cold Spring Harbor Symp. Quant. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.aat6806","article-title":"Dynamic DNA methylation: in the right place at the right time","volume":"361","author":"Luo","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118590_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ng1089","article-title":"Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals","volume":"33","author":"Jaenisch","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41576-020-00300-0","article-title":"The epigenetic basis of cellular heterogeneity","volume":"22","author":"Carter","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118590_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183391","article-title":"Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges","volume":"134","author":"Gold","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118590_bib14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3390\/cancers12082123","article-title":"DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118590_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12275-021-0674-y","article-title":"Prokaryotic DNA methylation and its functional roles","volume":"59","author":"Seong","year":"2021","journal-title":"J. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118590_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.74.010904.153721","article-title":"Eukaryotic cytosine methyl transferases","volume":"74","author":"Goll","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.118590_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2026.118590_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tibs.2014.05.002","article-title":"New concepts in DNA methylation","volume":"39","author":"Jeltsch","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1134\/S0006297915100193","article-title":"Role of restriction-modification systems in prokaryotic evolution and ecology","volume":"80","author":"Ershova","year":"2015","journal-title":"Biochem. (Mosc.)"},{"key":"10.1016\/j.ejmech.2026.118590_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/femsre\/fuw023","article-title":"DNA methyltransferases and epigenetic regulation in bacteria","volume":"40","author":"Adhikari","year":"2016","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118590_bib21","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1017\/S0029665118000150","article-title":"The role of DNA methylation in ageing and cancer","volume":"77","author":"Morgan","year":"2018","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.ejmech.2026.118590_bib24","article-title":"Emerging role of different DNA methyltransferases in the pathogenesis of cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118590_bib25","first-page":"631","article-title":"The role of mammalian DNA methyltransferases in the regulation of gene expression","volume":"10","author":"Turek-Plewa","year":"2005","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejmech.2026.118590_bib26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrg2651","article-title":"Rethinking how DNA methylation patterns are maintained","volume":"10","author":"Jones","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4161\/cc.1.6.270","article-title":"DNMT1 is a component of a multiprotein DNA replication complex","volume":"1","author":"Vertino","year":"2002","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.118590_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrg2540","article-title":"Linking DNA methylation and histone modification: patterns and paradigms","volume":"10","author":"Cedar","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1172\/JCI57292","article-title":"Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis","volume":"122","author":"Hlady","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118590_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/cancers14040961","article-title":"DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors","volume":"14","author":"Hoang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118590_bib31","first-page":"307","article-title":"Control elements of Dnmt1 gene are regulated in cell-cycle dependent manner","author":"Kishikawa","year":"2006","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.ejmech.2026.118590_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biochi.2015.06.019","article-title":"Dynamic expression of DNA methyltransferases (DNMTs) in oocytes and early embryos","volume":"116","author":"Uysal","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2026.118590_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35047554","article-title":"Genomic imprinting: parental influence on the genome","volume":"2","author":"Reik","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002750","article-title":"In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases","volume":"8","author":"Arand","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003439","article-title":"Mouse oocyte methylomes at base resolution reveal genome-wide accumulation of non-CpG methylation and role of DNA methyltransferases","volume":"9","author":"Shirane","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib36","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/hmg\/ddm179","article-title":"Role of the DNMT3 family in de novo methylation of imprinted and repetitive sequences during male germ cell development in the mouse","volume":"16","author":"Kato","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/416552a","article-title":"DNMT1 and DNMT3b cooperate to silence genes in human cancer cells","volume":"416","author":"Rhee","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib38","doi-asserted-by":"crossref","first-page":"16916","DOI":"10.1073\/pnas.262443999","article-title":"The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by DNMT3A","volume":"99","author":"Chedin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118590_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","article-title":"DNA methylation and human disease","volume":"6","author":"Robertson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib40","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/nar\/27.11.2291","article-title":"The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors","volume":"27","author":"Robertson","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib41","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1126\/science.1063852","article-title":"The role of DNA methylation in mammalian epigenetics","volume":"293","author":"Jones","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118590_bib42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome \u2014 biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biom8010011","article-title":"DOT1L and H3K79 methylation in transcription and genomic stability","volume":"8","author":"Katherine","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.118590_bib44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrg2072","article-title":"Transposable elements and the epigenetic regulation of the genome","volume":"8","author":"Slotkin","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.1083557","article-title":"Chromosomal instability and tumors promoted by DNA hypomethylation","volume":"300","author":"Eden","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118590_bib46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.cell.2019.01.043","article-title":"Genomic imprinting and physiological processes in mammals","volume":"176","author":"Tucci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc1279","article-title":"The history of cancer epigenetics","volume":"4","author":"Feinberg","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/molbev\/msx297","article-title":"Landscape of DNA methylation on the marsupial X","volume":"35","author":"Waters","year":"2018","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.ejmech.2026.118590_bib49","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1101\/gad.1422906","article-title":"Dosage compensation in mammals: fine-tuning the expression of the X chromosome","volume":"20","author":"Heard","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.118590_bib50","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.drudis.2019.08.006","article-title":"DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118590_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","article-title":"5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia","volume":"85","author":"Hoff","year":"1976","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.118590_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib54","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118590_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-022-01329-0","article-title":"Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line","volume":"14","author":"Aumer","year":"2022","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.118590_bib56","first-page":"5483","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002"},{"key":"10.1016\/j.ejmech.2026.118590_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/15287399009531383","article-title":"Teratogenicity of 5-azacytidine in the sprague-dawley rat","volume":"29","author":"Rosen","year":"1990","journal-title":"J. Toxicol. Environ. Health"},{"key":"10.1016\/j.ejmech.2026.118590_bib58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s42003-024-06271-w","article-title":"Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway","volume":"7","author":"Zhang","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib59","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1021\/jm00115a017","article-title":"Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues","volume":"34","author":"Driscoll","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib60","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1535-7163.MCT-11-0458","article-title":"DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118590_bib61","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1038\/srep03219","article-title":"Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress","volume":"3","author":"Yang","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118590_bib62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10565-021-09596-y","article-title":"The DNA methylation inhibitor RG108 protects against noise-induced hearing loss","volume":"37","author":"Zheng","year":"2021","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118590_bib63","first-page":"354","article-title":"Effects of RG108 on proliferation, apoptosis of human lung adenocarcinoma A549 cells and expression of RASSF1A gene","volume":"18","author":"Rui","year":"2009","journal-title":"Chin. J. Histochem. Cytochem"},{"key":"10.1016\/j.ejmech.2026.118590_bib64","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41419-020-02934-8","article-title":"Combined inhibition of JAK1\/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells","volume":"11","author":"She","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118590_bib65","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.bmcl.2013.01.085","article-title":"Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line","volume":"23","author":"Garc\u00eda-Dom\u00ednguez","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118590_bib66","first-page":"1","article-title":"Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia","author":"Pappalardi","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib67","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/hep.31642","article-title":"Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma","volume":"73","author":"Colyn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.118590_bib68","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41419-024-07156-w","article-title":"G9a\/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1","volume":"15","author":"Exposito","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118590_bib69","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.pbi.2007.06.008","article-title":"Role of histone and DNA methylation in gene regulation","volume":"10","author":"Vaillant","year":"2007","journal-title":"Curr. Opin. Plant Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib71","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.febslet.2010.11.010","article-title":"Histone arginine methylation","volume":"585","author":"Di Lorenzo","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2026.118590_bib72","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tibs.2013.08.002","article-title":"Tudor: a versatile family of histone methylation 'readers'","volume":"38","author":"Lu","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tcb.2024.06.001","article-title":"Roles of H3K4 methylation in biology and disease","volume":"35","author":"Wang","year":"2025","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","article-title":"Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance","volume":"23","author":"Padeken","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib75","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-Pyridone compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2026.118590_bib76","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib77","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118590_bib78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib79","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1101\/gad.415507","article-title":"The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells","volume":"21","author":"Bracken","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.118590_bib80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.4293","article-title":"EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas","volume":"23","author":"Mohammad","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular mechanisms directing PRC2 recruitment and H3K27 methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib84","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib85","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118590_bib86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1101\/gad.173930.111","article-title":"PRC2 directly methylates GATA4 and represses its transcriptional activity","volume":"26","author":"He","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.118590_bib87","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.molcel.2012.09.004","article-title":"EZH2 generates a methyl degron that is recognized by the DCAF1\/DDB1\/CUL4 E3 ubiquitin ligase complex","volume":"48","author":"Lee","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib88","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118590_bib89","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib90","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11427-024-2543-9","article-title":"Di-and tri-methylation of histone H3K36 play distinct roles in DNA double-strand break repair","volume":"67","author":"Chen","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib91","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00018-022-04352-9","article-title":"SETD2: from chromatin modifier to mu1tipronged regu1ator of the genome and beyond","volume":"79","author":"Molenaar","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13148-021-01187-2","article-title":"H3K36 trimethylation-mediated biological functions in cancer","volume":"13","author":"Xiao","year":"2021","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.118590_bib93","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/ijms20051029","article-title":"Roles of SETD2 in leukemia-transcription, DNA-damage, and beyond","volume":"20","author":"Skucha","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib94","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2024.03.005","article-title":"Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer","volume":"42","author":"Niu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib95","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s43018-021-00316-3","article-title":"SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes","volume":"3","author":"Xie","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib96","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02482","article-title":"SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint","volume":"3","author":"Carvalho","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118590_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70163","article-title":"SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability","volume":"15","author":"Mancini","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib98","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0960-9822(02)00901-6","article-title":"Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain","volume":"12","author":"Feng","year":"2002","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib99","doi-asserted-by":"crossref","first-page":"30421","DOI":"10.1074\/jbc.C200366200","article-title":"Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase","volume":"277","author":"Lacoste","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib101","first-page":"100","article-title":"Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib104","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","article-title":"Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML","volume":"34","author":"Liu","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2026.118590_bib105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152481","article-title":"Endothelial PRMT5 plays a crucial role in angiogenesis after acute ischemic injury","volume":"7","author":"Ye","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2026.118590_bib106","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone lysine methylation dynamics: establishment, regulation, and biological impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-016-0279-9","article-title":"Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives","volume":"9","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib108","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41580-019-0143-1","article-title":"The roles of DNA, RNA and histone methylation in ageing and cancer","volume":"20","author":"Michalak","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib109","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1093\/nar\/gkx747","article-title":"Multi-dimensional histone methylations for coordinated regulation of gene expression under hypoxia","volume":"45","author":"Lee","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib110","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/anie.200461346","article-title":"Epigenetics--an epicenter of gene regulation: histones and histone-modifying enzymes","volume":"44","author":"Biel","year":"2005","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118590_bib111","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cell.2013.01.052","article-title":"H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation","volume":"152","author":"Lauberth","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib112","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","article-title":"The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis","volume":"81","author":"Shilatifard","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.118590_bib113","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.adn6319","article-title":"Structural basis of H3K36 trimethylation by SETD2 during chromatin transcription","volume":"387","author":"Markert","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118590_bib114","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41594-023-01121-5","article-title":"Structure of histone deacetylase complex Rpd3S bound to nucleosome","volume":"30","author":"Li","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib115","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","article-title":"High-resolution profiling of histone methylations in the human genome","volume":"129","author":"Barski","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib116","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.molcel.2011.03.025","article-title":"Histone methylation by PRC2 is inhibited by active chromatin marks","volume":"42","author":"Schmitges","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib117","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib118","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molcel.2014.03.032","article-title":"Quiescence-induced LncRNAs trigger H4K20 trimethylation and transcriptional silencing","volume":"54","author":"Bierhoff","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib119","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.molcel.2024.02.030","article-title":"H3K4me1 facilitates promoter-enhancer interactions and gene activation during embryonic stem cell differentiation","volume":"84","author":"Kubo","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41576-020-0245-9","article-title":"Maternal H3K27me3-dependent autosomal and X chromosome imprinting","volume":"21","author":"Chen","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.tig.2021.06.017","article-title":"There is another: H3K27me3-mediated genomic imprinting","volume":"38","author":"Raas","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.ejmech.2026.118590_bib122","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41580-019-0151-1","article-title":"Roles and regulation of histone methylation in animal development","volume":"20","author":"Jambhekar","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib123","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41586-023-06711-3","article-title":"Asymmetric distribution of parental H3K9me3 in S phase silences L1 elements","volume":"623","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib124","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/nar\/gkt012","article-title":"Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity","volume":"41","author":"J\u00f8rgensen","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/13543776.2017.1316976","article-title":"EZH2 inhibitors: a patent review (2014-2016)","volume":"27","author":"Stazi","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118590_bib126","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib127","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib128","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy048.001","article-title":"42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","volume":"29","author":"Harb","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib129","doi-asserted-by":"crossref","first-page":"TPS398","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS398","article-title":"A phase 1b\/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Taplin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","volume":"61","author":"Kung","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib131","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib132","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib133","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2021-144676","article-title":"A global phase 2 study of valemetostat tosylate (Valemetostat) in patients with relapsed or refractory (r\/r) peripheral T-Cell lymphoma (PTCL), including r\/r adult T-Cell leukemia\/lymphoma (ATL) - valentine-PTCL01","volume":"138","author":"Foss","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib134","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood-2018-99-113379","article-title":"DS-3201, a potent EZH1\/2 dual inhibitor, demonstrates antitumor activity against non-hodgkin lymphoma (NHL) regardless of EZH2 mutation","volume":"132","author":"Honma","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib135","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/15548627.2020.1822628","article-title":"The role of autophagy in targeted therapy for acute myeloid leukemia","volume":"17","author":"Du","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2026.118590_bib136","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/pro.3129","article-title":"Targeting human SET1\/MLL family of proteins","volume":"26","author":"Vedadi","year":"2017","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib138","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ncomms2304","article-title":"Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors","volume":"3","author":"Yu","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118590_bib139","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2012.327","article-title":"Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118590_bib140","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/leu.2014.169","article-title":"The emerging roles of DOT1L in leukemia and normal development","volume":"28","author":"McLean","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118590_bib141","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","article-title":"H3K79 methylation profiles define murine and human MLL-AF4 leukemias","volume":"14","author":"Krivtsov","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib142","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib143","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jconrel.2015.09.023","article-title":"Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target","volume":"220","author":"Waters","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.118590_bib144","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib146","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib147","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-021-00339-6","article-title":"Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis","volume":"10","author":"Chava","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejmech.2026.118590_bib148","first-page":"19","article-title":"Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK\/ERK signaling pathway","volume":"9","author":"JiayuZhang","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118590_bib149","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/pro.3129","article-title":"Targeting human SET1\/MLL family of proteins","volume":"26","author":"Vedadi","year":"2017","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib150","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-16-1663","article-title":"The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription","volume":"77","author":"Wong","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib151","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S1097-2765(03)00477-5","article-title":"Partitioning and plasticity of repressive histone methylation states in mammalian chromatin","volume":"12","author":"Peters","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib152","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S1097-2765(03)00479-9","article-title":"Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains","volume":"12","author":"Rice","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib153","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1101\/gad.989402","article-title":"G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis","volume":"16","author":"Tachibana","year":"2002","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2026.118590_bib154","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fimmu.2015.00487","article-title":"Functional role of G9a histone methyltransferase in cancer","volume":"6","author":"Casciello","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118590_bib155","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.2027411","article-title":"H3K9 methyltransferase G9a and the related molecule GLP","volume":"25","author":"Shinkai","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.118590_bib156","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ccell.2018.09.001","article-title":"MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis","volume":"34","author":"Tu","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib157","doi-asserted-by":"crossref","first-page":"19363","DOI":"10.1073\/pnas.0906142106","article-title":"G9a selectively represses a class of late-replicating genes at the nuclear periphery","volume":"106","author":"Yokochi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118590_bib158","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase","volume":"25","author":"Homon","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib159","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/nar\/gky1230","article-title":"FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer","volume":"47","author":"Chae","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1560","article-title":"Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294","volume":"16","author":"Chang","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib161","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41420-018-0035-8","article-title":"BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression","volume":"4","author":"Woo","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.118590_bib162","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1172\/JCI57349","article-title":"G9a interacts with snail and is critical for Snail-mediated E-cadherin repression in human breast cancer","volume":"122","author":"Dong","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118590_bib163","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm.4257","article-title":"Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome","volume":"23","author":"Kim","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib164","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3324\/haematol.2019.223883","article-title":"SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation","volume":"105","author":"Ropa","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.118590_bib165","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/0008-5472.CAN-14-2796","article-title":"Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage","volume":"75","author":"Wu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib166","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.1021\/acs.jmedchem.9b00522","article-title":"Discovery of a potent and selective fragment-like inhibitor of methyllysine reader protein spindlin 1 (SPIN1)","volume":"62","author":"Xiong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib167","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-018-0896-8","article-title":"Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1\u03b1 and APC2 gene expression in non-small cell lung cancer","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib168","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib169","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.canlet.2016.07.009","article-title":"G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status","volume":"380","author":"A","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118590_bib170","article-title":"The histone methyltransferase inhibitor A-366 uncovers a role for G9a\/GLP in the epigenetics of leukemia","volume":"10","author":"William","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118590_bib171","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib172","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JU.0000000000000781.01","article-title":"Re: inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"203","author":"Atala","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.ejmech.2026.118590_bib173","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejmech.2016.06.028","article-title":"Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines","volume":"122","author":"Kondengaden","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib174","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature05458","article-title":"Histone arginine methylation regulates pluripotency in the early mouse embryo","volume":"445","author":"Torres-Padilla","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib175","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.celrep.2013.11.025","article-title":"PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex","volume":"5","author":"Ly","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118590_bib176","article-title":"Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma","volume":"7","author":"Drew","year":"2017","journal-title":"Rep"},{"key":"10.1016\/j.ejmech.2026.118590_bib177","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.24883","article-title":"TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma","volume":"9","author":"Nakayama","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118590_bib178","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1158\/1538-7445.AM2018-4313","article-title":"Methylated BAF155 promotes cancer metastasis by cooperating with BRD4 to potentiate genes addicted to super-enhancers","volume":"78","author":"Kim","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156242","article-title":"C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1","volume":"168","author":"Sun","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2026.118590_bib180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2021.11.001","article-title":"PRMT4 inhibitor TP-064 impacts both inflammatory and metabolic processes without changing the susceptibility for early atherosclerotic lesions in male apolipoprotein E knockout mice","volume":"338","author":"Zhang","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2026.118590_bib181","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1021\/acs.jmedchem.3c02315","article-title":"A CARM1 inhibitor potently suppresses breast cancer both in vitro and in vivo","volume":"67","author":"Peng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib182","first-page":"2041","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond, cell. Mol","volume":"72","author":"Stopa","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.118590_bib183","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","article-title":"PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118590_bib184","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib185","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.08.018","article-title":"Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma","volume":"32","author":"Braun","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118590_bib187","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/hep.31864","article-title":"Myelocytomatosis-protein arginine n-methyltransferase 5 axis defines the tumorigenesis and immune response in hepatocellular carcinoma","volume":"74","author":"Luo","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.118590_bib188","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114558","article-title":"MST2 methylation by PRMT5 inhibits hippo signaling and promotes pancreatic cancer progression","volume":"42","author":"Sun","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118590_bib189","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-DDT02-04","article-title":"Abstract DDT02-04: a novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models","volume":"77","author":"Brehmer","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib190","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118590_bib191","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib193","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-024-03270-x","article-title":"PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands","volume":"44","author":"Mishra","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib195","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1074\/jbc.M110.202416","article-title":"Protein-arginine methyltransferase 1 (PRMT1) methylates ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes","volume":"286","author":"Butler","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib196","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13543776.2019.1567711","article-title":"A patent review of arginine methyltransferase inhibitors (2010\u20132018), expert opin","volume":"29","author":"Li","year":"2019","journal-title":"Ther. Pat"},{"key":"10.1016\/j.ejmech.2026.118590_bib197","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/acsmedchemlett.8b00014","article-title":"LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity","volume":"9","author":"Bonday","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118590_bib198","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41388-024-02996-4","article-title":"LPCAT2 inhibits colorectal cancer progression via the PRMT1\/SLC7A11 axis","volume":"43","author":"Cao","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118590_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113831","article-title":"PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity","volume":"43","author":"Djajawi","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118590_bib200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41419-024-06544-6","article-title":"PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118590_bib201","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-023-38443-3","article-title":"PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118590_bib202","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41419-024-06898-x","article-title":"PRMT1 promotes warburg effect by regulating the PKM2\/PKM1 ratio in non-small cell lung cancer","volume":"15","author":"Peng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118590_bib203","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12964-024-01506-z","article-title":"PRMT1 in human neoplasm: cancer biology and potential therapeutic target","volume":"22","author":"Shen","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2026.118590_bib204","doi-asserted-by":"crossref","first-page":"13479","DOI":"10.1074\/jbc.M114.636050","article-title":"PRMT1 is a novel regulator of epithelial-mesenchymal-transition in nn-small cell lung cancer","volume":"290","author":"Avasarala","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib205","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1172\/JCI82826","article-title":"PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response","volume":"125","author":"Liao","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118590_bib206","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.exphem.2016.03.009","article-title":"Arginine methyltransferases in normal and malignant hematopoiesis","volume":"44","author":"Greenblatt","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.118590_bib207","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"Anthony B","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113831","article-title":"PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity","volume":"43","author":"Djajawi","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118590_bib209","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/2326-6066.CIR-21-0614","article-title":"Inhibiting type I arginine methyltransferase activity promotes T cell-mediated antitumor immune responses","volume":"10","author":"Fedoriw","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccell.2019.06.004","article-title":"Richard, M-TAP dance: targeting PRMT1 and PRMT5 family members to push cancer cells over the edge - sciencedirect","volume":"36","author":"Nivine","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117625","article-title":"Discovery of a first-in-class protein arginine methyltransferase 1 (PRMT1) degrader for nonenzymatic functions studies","volume":"291","author":"Ma","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118590_bib212","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib213","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.2019001282","article-title":"PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD + acute myeloid leukemia","volume":"134","author":"He","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118590_bib214","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/ATVBAHA.124.322249","article-title":"Arginine methylation by PRMT1 affects ADAMTS13 secretion and enzymatic activity","volume":"45","author":"Liu","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2026.118590_bib215","article-title":"Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma","volume":"14","author":"Nguyen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118590_bib216","first-page":"9","article-title":"Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer","volume":"130","author":"Sheyu Zhang","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib217","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1038\/s41467-024-52507-y","article-title":"PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma","volume":"15","author":"Walton","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118590_bib218","article-title":"PRMT1 promotes the self-renewal of leukemia stem cells by regulating protein synthesis","volume":"12","author":"Zhou","year":"2024","journal-title":"Adv. Sci"},{"key":"10.1016\/j.ejmech.2026.118590_bib219","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","article-title":"Role of RNA modifications in cancer","volume":"20","author":"Barbieri","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib220","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41392-022-01175-9","article-title":"RNA modifications: importance in immune cell biology and related diseases","volume":"7","author":"Cui","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118590_bib221","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118590_bib222","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-022-01558-0","article-title":"Targeting the RNA m(6)A modification for cancer immunotherapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib223","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.gpb.2017.03.003","article-title":"Epitranscriptomics: toward a better understanding of RNA modifications","volume":"15","author":"Xiong","year":"2017","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.ejmech.2026.118590_bib224","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","article-title":"The roles and implications of RNA m(6)A modification in cancer","volume":"20","author":"Deng","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-023-01785-z","article-title":"Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer","volume":"22","author":"Ortiz-Barahona","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib226","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","article-title":"Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers","volume":"74","author":"Shi","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118590_bib227","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41388-021-01978-0","article-title":"NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization","volume":"40","author":"Su","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118590_bib228","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","article-title":"The potential role of RNA N6-methyladenosine in cancer progression","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib229","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1038\/s41467-021-26718-6","article-title":"N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118590_bib230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-022-01304-5","article-title":"Crosstalk among m(6)A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib231","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41590-023-01548-4","article-title":"m(6)A RNA modification regulates innate lymphoid cell responses in a lineage-specific manner","volume":"24","author":"Zhang","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.118590_bib232","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1021\/acs.accounts.3c00448","article-title":"Emerging roles of RNA methylation in development","volume":"56","author":"Wang","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib233","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","article-title":"The role of m6A RNA methylation in cancer metabolism","volume":"21","author":"An","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118590_bib234","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-019-0805-7","article-title":"The interplay between m6A RNA methylation and noncoding RNA in cancer","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib235","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/cr.2017.55","article-title":"5-methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m(5)C reader","volume":"27","author":"Yang","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib236","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/nar\/gkad1193","article-title":"Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A","volume":"52","author":"Gu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118590_bib237","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-022-01285-5","article-title":"The potential role of N(7)-methylguanosine (m7G) in cancer","volume":"15","author":"Luo","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118590_bib238","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118590_bib239","first-page":"1","article-title":"Patent landscape of small molecule inhibitors of METTL3 (2020-present)","author":"Wu","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118590_bib240","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02765-6","article-title":"Epitranscriptomic advances in normal and malignant hematopoiesis","author":"Eleftheriou","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118590_bib241","doi-asserted-by":"crossref","first-page":"18114","DOI":"10.1021\/acs.jmedchem.5c01570","article-title":"Small-molecule inhibitors targeting RNA m(6)A modifiers for cancer therapeutics: latest advances and future perspectives","volume":"68","author":"Tang","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:33:35Z","timestamp":1771911215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":241,"alternative-id":["S0223523426000358"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118590","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic enzyme inhibitors targeting DNA, histone, and RNA methylation: Mechanisms and therapeutic applications in cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118590"}}